Cargando…

Neutralization of B-Cell Activating Factor (BAFF) by Belimumab Reinforces Small Molecule Inhibitor Treatment in Chronic Lymphocytic Leukemia

SIMPLE SUMMARY: Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in Western countries. Despite the substantial progress achieved by the recent introduction of the novel small molecule inhibitors idelalisib, ibrutinib and venetoclax in CLL treatment, therapy resistance occurs fr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tandler, Claudia, Schmidt, Moritz, Heitmann, Jonas S., Hierold, Julia, Schmidt, Jonas, Schneider, Pascal, Dörfel, Daniela, Walz, Juliane, Salih, Helmut R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7598196/ https://www.ncbi.nlm.nih.gov/pubmed/32977449 http://dx.doi.org/10.3390/cancers12102725

Ejemplares similares

Inhibition of Membrane-Bound BAFF by the Anti-BAFF Antibody Belimumab
por: Kowalczyk-Quintas, Christine, et al.
Publicado: (2018)

BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus
por: Shin, Woori, et al.
Publicado: (2018)

B cell alterations during BAFF inhibition with belimumab in SLE
por: Ramsköld, Daniel, et al.
Publicado: (2018)

Immunoprofiling of 4-1BB Expression Predicts Outcome in Chronic Lymphocytic Leukemia (CLL)
por: Kaban, Kübra, et al.
Publicado: (2021)

Immunopeptidome Diversity in Chronic Lymphocytic Leukemia Identifies Patients with Favorable Disease Outcome
por: Marconato, Maddalena, et al.
Publicado: (2022)

Receptor Activator of NF-κB (RANK) Confers Resistance to Chemotherapy in AML and Associates with Dismal Disease Course
por: Clar, Kim L., et al.
Publicado: (2021)

Baff Mediates Survival of Peripheral Immature B Lymphocytes
por: Batten, Marcel, et al.
Publicado: (2000)

HLA-DR Presentation of the Tumor Antigen MSLN Associates with Clinical Outcome of Ovarian Cancer Patients
por: Tegeler, Christian M., et al.
Publicado: (2022)

Genetic Loss of LCK Kinase Leads to Acceleration of Chronic Lymphocytic Leukemia
por: Märklin, Melanie, et al.
Publicado: (2020)

Data for the crystal structure of APRIL–BAFF–BAFF heterotrimer
por: Maskos, Klaus, et al.
Publicado: (2015)

Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma
por: Heitmann, Jonas S, et al.
Publicado: (2020)

Prevalence of COVID-19-associated symptoms during acute infection in relation to SARS-CoV-2-directed humoral and cellular immune responses in a mild-diseased convalescent cohort
por: Tegeler, Christian M., et al.
Publicado: (2022)

Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents
por: Lenert, Aleksander, et al.
Publicado: (2015)

Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations
por: Mackay, Fabienne, et al.
Publicado: (1999)

Development of a Novel BAFF Responsive Cell Line Suitable for Detecting Bioactive BAFF and Neutralizing Antibodies against BAFF-Pathway Inhibiting Therapeutics
por: Hu, Jenny, et al.
Publicado: (2014)

Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia
por: Nelde, Annika, et al.
Publicado: (2021)

CD105 (Endoglin) as negative prognostic factor in AML
por: Kauer, Joseph, et al.
Publicado: (2019)

BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro
por: Kauer, Joseph, et al.
Publicado: (2022)

Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression
por: Pahl, Madeleine V., et al.
Publicado: (2010)

The effects of BAFF on T lymphocytes in chronic obstructive pulmonary disease
por: Gao, Shupei, et al.
Publicado: (2020)

Long-Term Follow-Up of COVID-19 Convalescents—Immune Response Associated with Reinfection Rate and Symptoms
por: Seller, Anna, et al.
Publicado: (2023)

BAFF 60-mer, and Differential BAFF 60-mer Dissociating Activities in Human Serum, Cord Blood and Cerebrospinal Fluid
por: Eslami, Mahya, et al.
Publicado: (2020)

Belimumab use during pregnancy: Interim results of the belimumab pregnancy registry
por: Juliao, Patricia, et al.
Publicado: (2022)

Association of variants in BAFF (rs9514828 and rs1041569) and BAFF-R (rs61756766) genes with the risk of chronic lymphocytic leukemia
por: Jasek, Monika, et al.
Publicado: (2016)

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
por: Heitmann, Jonas S., et al.
Publicado: (2023)

BAFF and BAFF-Receptor in B Cell Selection and Survival
por: Smulski, Cristian R., et al.
Publicado: (2018)

Letter in reply: Crusted scabies mimicking a lupus flare after rituximab and belimumab
por: Androsov, Grigoriy, et al.
Publicado: (2021)

Platelet-Expressed TNFRSF13B (TACI) Predicts Breast Cancer Progression
por: Hinterleitner, Clemens, et al.
Publicado: (2021)

Poor immunogenicity upon SARS-CoV-2 mRNA vaccinations in autoimmune SLE patients is associated with pronounced EF-mediated responses and anti-BAFF/Belimumab treatment
por: Faliti, Caterina E., et al.
Publicado: (2023)

BAFF Controls Neural Cell Survival through BAFF Receptor
por: Tada, Satoru, et al.
Publicado: (2013)

Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives
por: Heitmann, Jonas S., et al.
Publicado: (2021)

Elevated SARS-CoV-2-Specific Antibody Levels in Patients with Post-COVID Syndrome
por: Hackenbruch, Christopher, et al.
Publicado: (2023)

CD40- and CD95-specific antibody single chain-Baff fusion proteins display BaffR-, TACI- and BCMA-restricted agonism
por: Nelke, Johannes, et al.
Publicado: (2020)

Identification of CD105 (endoglin) as novel risk marker in CLL
por: Greiner, Sarah M., et al.
Publicado: (2022)

An update on belimumab for the treatment of lupus
por: Thanou-Stavraki, Aikaterini, et al.
Publicado: (2011)

Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015)

Belimumab in Systemic Lupus Erythematosus
por: Srivastava, Ankita
Publicado: (2016)

Modifications of the BAFF/BAFF-Receptor Axis in Patients With Pemphigus Treated With Rituximab Versus Standard Corticosteroid Regimen
por: Hébert, Vivien, et al.
Publicado: (2021)

T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals
por: Bilich, Tatjana, et al.
Publicado: (2021)

The actions of BAFF in B-lymphocyte maturation and its effects on the development of autoimmune disease
por: Melchers, F
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_tk9tnouisp150h5oev9cbhplc2